Skip to main content

InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) Pearsanta Inc. Enters LOI to Acquire Natural State Laboratories and Natural State Genomics

Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, today announced the signing of an exclusive non-binding letter of intent (“LOI”) by its wholly owned subsidiary, Pearsanta(TM) Inc., to acquire both Natural State Laboratories LLC (“NSL”) and Natural State Genomics LLC (“NSG”) (collectively, “Natural State Entities” or “NSL/NSG”). Headquartered in Little Rock, Arkansas, the Natural State Entities are a premier full-service laboratory offering diagnostic, molecular, genetic, and toxicology services. “Our goal is to build out our innovations into growing portfolio companies as we endeavor to expand their capabilities organically and via M&A,” said Amro Albanna, Aditxt co-founder and CEO, and current interim chairman and CEO of Pearsanta. “This potential acquisition of NSL/NSG is an important step for the growth of Pearsanta and value creation for our shareholders.”

To view the full press release, visit

About Aditxt Inc.

Aditxt is a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system. Headquartered in Richmond, Virginia, the company has operations in Silicon Valley, California, and New York, New York. Aditxt’s mission “Making Promising Innovations Possible, Together” is defined by its growing ecosystem of research institutions, global industry partners and shareholders who inform and inspire its mission. Aditxt’s diverse innovation portfolio includes: Adimune(TM), aimed at developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir(TM), focused on identifying, developing, and commercializing new ways to treat infectious diseases; and Pearsanta(TM), which intends to offer personalized immune monitoring for a wide range of health conditions, including hereditary cancer, wounds and cardiomyopathy. For more information, visit the company’s websites at and

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.